We need to engage representative patients’ community rather than ‘expert patients’ to increase impact of research in the era of personalised medicine: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Shaw

Baker

. Expert patient: Dream or nightmare? BMJ 2004; 328(7442): 723–724.

Fitzpatrick

. Expert patients? Br J Gen Practice 2004; 54(502): 405.

Department of Health. Saving lives: Our healthier nation. London: The Stationery Office, 1999.

Cordier

. The expert patient: Towards a novel definition. Eur Resp J 2014; 44: 853–857.

Vicente

Ballensiefen

Jönsson

J-I

, et al. How personalised medicine will transform healthcare by 2030: The ICPerMed vision. J Transl Med 2020; 18: 180.

Asher Mullard

. Parsing clinical success rates. Nat Rev Drug Disc 2016; 15: 447.

European Medicines Agency. EMA/CHMP/539146/2013 Committee for Medicinal Products for Human Use (CHMP). Amsterdam: European Medicines Agency; 2019.

Burke

Sussman

Kent

, et al. Three simple rules to ensure reasonably credible subgroup analyses. BMJ 2015; 351: h5651.

Filbey

Zhu

D’Angelo

, et al. Improving representativeness in trials: A call to action from the Global Cardiovascular Clinical Trialists Forum. Eur Heart J 2023; 44(11): 921–930.

10.

Stromme

. We cannot continue to ignore heterogeneity in ALS. Biocentury, October, 2024. https://www.biocentury.com/article/653707/we-cannot-continue-to-ignore-heterogeneity-in-als